Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

Full preliminary results for year 2006-7

Abcam has published preliminary results for the 12 months ended 30 June 2007.

Highlights include sales increased 26.6% to £24.5m (2006: £19.4m), pre-tax profits increased 18.1% to £5.7m (2006: £4.8m), product range grew to 33,900 antibodies and related products (2006: 23,200) and three licensing deals agreed giving Abcam exclusive distribution rights to over 4,000 existing and future complementary products.

The high-throughput production (HTP) laboratory was built to boost the number of high-margin inhouse products. Operations began on schedule and the first antibodies will be ready for sale later this calendar year. A new subsidiary in Tokyo is trading well and will help Abcam further develop its fast-growing Asia-Pacific business.

David Cleevely, Abcam’s Chairman, said: “This has been another highly successful year for Abcam. We are entering the current year with an exciting platform for growth and our cash generation is such that we have been able to significantly increase the distribution of our profits to shareholders by raising our dividend policy to 33% of our after-tax profits. Current trading remains strong and the Board is confident of the outlook for 2008.”

You can download the full preliminary year results from our Key dates / Reports and accounts section.

---

back to news list